Testing ASC50 tablets for plaque psoriasis
Part of Immune system & allergy, Skin clinical trials.
This study tests an investigational tablet called ASC50 for plaque psoriasis. It aims to see if it is safe and works well for people with this skin condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have plaque psoriasis.
- You have good vein access for blood draws.
- You are not pregnant, breastfeeding, or planning pregnancy during the study and for 3 months after.
- You have not used certain immune-suppressing medicines (like methotrexate or cyclosporine) in the last 4 weeks.
- You do not have any other medical or mental health condition that could make the study risky for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
This early-phase study tests an experimental oral tablet (UA026) in people with moderate to severe plaque psoriasis. The purpose is to see how safe and effective the drug is, and how it works in the body.
This trial tests an experimental pill called D-2570 for people with moderate to severe plaque psoriasis. It aims to see if the pill can safely improve skin symptoms like redness, scaling, and thickness.
This study tests a new oral pill (HSK47388) for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective in reducing the severity and area of psoriasis over 12 weeks.
This trial tests an oral medication called ICP-332 versus a placebo (a pill with no active drug) for people with moderate to severe plaque psoriasis. The goal is to see if ICP-332 can improve skin symptoms and be safe.
This trial tests a new study drug (ZP9830) to see if it is safe and works well for people with plaque psoriasis. You would receive the treatment for 8 weeks, and the study will check how your skin responds.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.